In end-stage heart failure, mechanical ventricular assist devices (VAD) are being used as bridge-to-transplantation, as a bridge-to-recovery, or as the definitive therapy. We tested the hypothesis that myocardial implantation of autologous bone marrow mononuclear cells (BMNC) increases the likelihood of successful weaning from left VAD (LVAD) support. Ten patients (aged 14-60 years) with deteriorating heart function underwent LVAD implantation and concomitant implantation of autologous BMNC. Bone marrow was harvested prior to VAD implantation and BMNC were prepared by density centrifugation. Two patients received a pulsatile, extracorporeal LVAD and eight a nonpulsatile implantable device. Between 52 and 164 × 10 7 BMNC containing between 1 and 12 × 10 6 CD34 + cells were injected into the LV myocardium. There was one early and one late death. The median time on LVAD support was 243 days (range 24-498 days). Repeated echocardiographic examinations under increased hemodynamic load revealed a significant improvement of LV function in one patient. Three patients underwent heart transplantation, and four patients remain on LVAD support >1 year without evidence of recovery. Only one patient was successfully weaned from LVAD support after 4 months, and LV function has remained stable ever since. In patients with endstage cardiomyopathy, intramyocardial injection of BMNC at the time of LVAD implantation does not seem to increase the likelihood of successful weaning from VAD support. Other cell-based strategies should be pursued to harness the potential of cell therapy in LVAD patients.
INTRODUCTION nent death is the immediate implantation of a mechanical cardiac assist device. This is often planned as a Cell-based regenerative medicine for heart disease has recently gained widespread attention. Although the bridge-to-transplantation or as the definitive therapy; in some instances, however, heart function recovers and initial hypothesis-transdifferentiation of bone marrow stem cells into cells with cardiomyocyte phenotype-allows for weaning from the mechanical support and ultimately explantation of the device (5, 7, 10) . The likeli-has never been conclusively proven (20) , there is a large body of information indicating that, via several other hood of successful weaning is small and depends on an unknown number of patient-, disease-, and device-related mechanisms, marrow-derived cells do have beneficial effects on diseased myocardium. Clinical trials have so factors. Theoretically, bone marrow-derived progenitor cells may aid the recovery of failing myocardium by far mainly focused on patients with myocardial infarction, and a moderate improvement of heart function has promoting angiogenesis, suppressing cardiomyocyte apoptosis, and modulating extracellular matrix turnover (8, been shown in some, but not all, studies (1, 23) . There is very little information, however, on cell therapy for pa-13,16,18).
We therefore designed a pilot study to test the hy-tients who need novel therapeutic approaches most urgently, namely those with end-stage heart failure. When pothesis that the likelihood of successful weaning from mechanical support in patients with terminal heart fail-after 2 weeks for implantation of a long-term compatible assist device and evaluation for heart transplantation. ure is increased when autologous bone marrow mononuclear cells (BMNC) are implanted in the myocardium.
The study was approved by the local ethics committee and conforms with the principles outlined in the Declaration of Helsinki.
MATERIALS AND METHODS

Cell Preparation
Ten consecutive patients with end-stage heart failure, who were admitted to our hospital due to the onset of Bone marrow aspiration was performed in local anesthesia several hours prior to the operation, either in the acute decompensation, were enrolled in the study. Their preoperative characteristics are summarized in Table 1 .
morning when surgery was scheduled for the afternoon, or on the previous day when surgery was scheduled for The underlying disease had been classified as idiopathic dilative cardiomyopathy, although one patient also had the next morning. On average, 74 ml marrow was collected in heparinized syringes (range 45-115 ml). The a history of ischemic heart disease and another patient anamnestic evidence of previous virus infection. All pa-marrow was taken to the clean room facility of the Pediatric Bone Marrow Transplant Program at Charité Uni-tients were male, and the median age was 50.5 years, ranging from 14 to 60 years. The interval between versitätsmedizin, where a mononuclear cell product was prepared by Ficoll density centrifugation. Cells were re-known onset of the disease and admission to our institution ranged between 2 and 163 months (median 53 suspended in 8 ml autologous serum and filled in standard insulin syringes. When overnight storage was nec-months) All patients required catecholamine infusions to maintain hemodynamic stability. The decision for assist essary, this was done at 4°C. Cells were not labeled for detection in vivo or on histology. device implantation was made because cardiac output remained insufficient for adequate organ perfusion, Surgery while all pharmacologic treatment options had been exhausted. In principle, all patients were considered subse-
The techniques of left ventricular assist device implantation have been summarized elsewhere (4, 6, 11) . quent candidates for heart transplantation, should LV function not recover during VAD support. One patient, Briefly, a median sternotomy was performed and the patients were placed on cardiopulmonary bypass. The out-a 14-year-old boy, had initially presented to a referring center in cardiogenic shock requiring cardiopulmonary flow cannula was connected with the ascending aorta by end-to-side anastomosis, and the inflow cannula was resuscitation, where he was placed on a device for shortterm mechanical circulatory support (centrifugal pump inserted into the apex of the left ventricle ( Fig. 1 ). This concept was the same for all LVAD modifications. system). Because LV function did not immediately recover and the need for long-term mechanical support When an extracorporeal pump chamber was used (Berlin Heart EXCOR, Berlin Heart Mediprodukt GmbH, Ber-was anticipated, this patient was referred to our center lin, Germany), the cannulas were guided through the ing is not possible, patients are placed on the waiting list for heart transplantation, which is performed as soon skin below the ribcage, and were connected with a pneumatically driven pump chamber. When an implantable as an organ becomes available. The waiting time to transplantation for a patient depends on the listing status LVAD was used, the cannulas were connected with a turbine-driven continuous flow pump that was placed (transplantable, urgent, or high urgent) and can range between a few months and several years. within the chest (Berlin Heart INCOR). Then 24 injections of cell suspension were distributed all over the ac-Histology cessible free wall of the left ventricle. Initially, 24 sepa-At the time of LVAD implantation, LV myocardium rate syringes with 0.3 ml cell suspension each were samples were obtained from the apical cannulation site, used. Later, the cell product was loaded in eight syringes fixed in formalin, embedded in paraffin, and sectioned per 1 ml. Once the procedure was completed, patients for histologic analysis. In four patients, tissue was availwere brought to the ICU and transferred to the normal able during follow-up, at the time of device explantation ward when hemodymanics and hemostasis had stabior heart transplantation, respectively. Sections were lized. Particular care was taken to monitor right ventricroutinely stained by hematoxylin & eosin and studied ular function, and pharmacologic therapy including niby light microscopy. To assess the degree of compensatric oxide inhalation was used liberally whenever tory cardiomyocyte hypertrophy, the diameter of crossimpaired right heart output was suspected.
sectioned individual cardiomyocytes was measured, and Echocardiography the average cardiomyocyte diameter was calculated for each patient. Moreover, myocardial fibrosis was quanti-Echocardiography was performed before the operafied following Sirius red staining of tissue sections. Imtion and on a daily basis during the ICU stay, followed ages were digitalized, and a customized software was by weekly examinations until discharge. Studies were used to quantify the amount of interstitial collagen depodone using a Vivid Seven digital ultrasound system sition in a defined area of 1 mm 2 . (General Electrics, Horton, Norway). Left ventricular ejection fraction was determined by manual tracing of Statistics end-systolic and end-diastolic endocardial borders using Data are expressed as mean and SD or as median and four-chamber (4Ch) and two-chamber (2Ch) views, emrange when appropriate. Serial quantitative echocardiogploying biplane Simpson's method. Left ventricular endraphy and histology data were compared by paired tdiastolic (LVEDD) and end-systolic (LVESD) diameter test. Intergroup comparisons were not performed in this were measured on M-mode echocardiograms using stanpilot study. dard techniques, and the shortening fraction was calculated accordingly. In addition, geometric parameters RESULTS such as left ventricular inner diastolic diameter (LVIDd),
Cell Product short to long axis ratio, sphericity index, and changes in regional myocardial deformation using radial strain All cell products met the release criteria in terms of measurements were assessed when the possibility of bacterial contamination, viability, and stem cell content. weaning from LVAD support was seriously considered Serologic studies indicated previous cytomegaly virus (15) . infection in one patient and Ebstein Barr virus persis-In every patient, a "pump-stop" echocardiogram was tence in another. These were not considered exclusion performed 2 months after LVAD implantation to evalucriteria and had no impact on patient survival. The meate the recovery of left ventricular function, both at rest dian total nucleated cell count in the crude marrow prepand under dobutamine stress. Here, LVAD support was aration was 128 × 10 7 (range 52-164 × 10 7 ), and the meincrementally reduced under continuous echocardiodian mononuclear cell count in the final product was graphic and hemodynamic monitoring. If possible, LVAD 20 × 10 7 (range 14-47 × 10 7 ). Of those, 3.2 × 10 6 (range support was turned off for approximately 30 min, and 1-12 × 10 6 ) cells were CD34 + by FACS analysis. There LV as well as RV function and dimensions were rewas no apparent association between the total or CD34 + corded. To assess the possibility of successful permacell count and the patients' age or severity of disease. nent weaning off LVAD support, we used an algorithm Surgery that is mainly based on echocardiographic criteria such as left ventricular ejection fraction and left ventricular LVAD implantation was carried out as planned in nine patients. In one patient (patient number 4 in Table  end -diastolic diameter (6) . When a patient is considered suitable for LVAD weaning and repeated pump-stop 1), it turned out that, despite maximum inotropic support and afterload reduction, the right ventricle was not able echos have produced similar results, he is taken to the operating room for device explantation. If LVAD wean-to maintain sufficient output after implantation of the LVAD, so that an additional right ventricular assist device was implanted (biventricular assist device, BVAD). All patients survived the surgical procedure and received inotrope infusion for support of right ventricular function and regulation of peripheral blood pressure. Inotropic support could be discontinued after an average of 3 days (range 0-6 days). Patients were weaned off mechanical ventilation after a median of 3 days, ranging from 0 to 14 days. The average ICU stay was 15 days, ranging from 3 to 30 days. In eight patients, no major complications (i.e., thrombembolism, cerebral infarction, hemorrhage, or device-related infections) occurred during postoperative follow-up. Two patients, however, suffered serious complications in terms of pneumonia and/or wound/device infection. Despite maximum antibiotic therapy, the infection could not be eliminated or performed under full anticoagulation. Overall, the median LVEF had minimally increased from 18.1% (range 11-24%) to 22.3% (range 8-56%, p = 0.3). The average In seven of the eight surviving patients, however, left LVEDD had decreased from 78 ± 10 mm to 65 ± 12 mm ventricular contractility and dimensions during pump-(p = 0.02). LVESD had decreased from 70 ± 11 mm to stop echocardiography did not meet the criteria that indi-59 ± 13 mm (p = 0.05), and the shortening fraction had cate suitability for successful weaning off LVAD support. slightly increased from 9 ± 2% to 12 ± 8% (p = 0.2).
In three of those, heart transplantation was performed after 84, 221, and 305 days on LVAD support, respectively. All three patients survived the transplantation procedure and were discharged home. At present, four patients are still on LVAD support, for 335, 336, 441, and 568 days, respectively. In all of them, repeated pump-stop echocardiograms showed no sign of recovery of LV function. Having been on LVAD support for at least 10 months without change in LV function, no recovery is expected anymore. All four patients are listed for heart transplantation, which will be carried out as soon as a matching organ becomes available. Only one patient, the 14-year-old boy who was referred to us in cardiogenic shock on short-term extracorporeal support, met the LVAD weaning criteria during the 2-month pump-stop echocardiography study. Two further pump-stop echocardiograms were performed on a monthly basis in this patient, and the sustained changes in left ventricular geometry and regional defor- plantation procedure and was extubated on postoperative 10). Long-term results in these patients have been satisfactory for up to 9 years of follow-up after explantation day 1. Medical treatment was continued with ACE inhibitors and diuretics, and 4 months after LVAD explan- (5) . Occasionally, there is also a patient with end-stage ischemic heart disease and a history of multiple myocar-tation the patient presented with near normal left ventricular geometry and a further improvement in regional dial infarctions who recovers during LVAD support, although this is exceedingly rare. The mechanisms of function. At present, his follow-up covers 2 years and has been uneventful. myocardial recovery remain elusive. Adjuvant therapies, including immunoabsorption, pharmacologic heart fail-Histology ure treatment, and administration of antioxidants and microelements (19) or clenbuterol (2) during LVAD In four patients, post-cell therapy myocardial tissue samples could be compared with those obtained prior support, have been used to promote cardiac recovery during ventricular unloading. In heart failure, myocytes to cell injection and LVAD implantation. Because the autologous cells were not labeled, it was not possible to are damaged and cellular as well as extracellular tissue components are deharmonized, leading to functional and determine the fate of the injected marrow cells or their progeny. The data on cardiomyocyte diameter and inter-structural remodeling. First and foremost, rapid LVAD implantation ensures survival of the patient. Second-stitial collagen deposition are summarized in Figure 4 . Interestingly, the only patient in whom an increase in arily, unloading of the heart enables the myocardium to recover without further damage to tissue components cardiomyocyte diameter indicated hypertrophic myocyte growth was the one who could be successfully weaned and to achieve reverse remodeling. Because dead cardiomyocytes cannot be replaced by new cardiomyocytes-off LVAD support (from 15 to 20 µm). In two other cases, cardiomyocyte diameter markedly decreased (from unless cell therapy would induce a net increase in cardiomyocyte number-repair will hypothetically be per-26 to 15 µm, and from 23 to 11 µm, respectively), intuitively consistent with the concept of reducing the work formed through moderate symmetrical hypertrophy of the myocytes and by filling the intercellular spaces with load of the heart. Cardiomyocyte diameter remained unchanged in the fourth patient. The data on myocardial extracellular matrix. A picture such as this was indeed observed in our one "successful" patient. Such "reverse fibrosis are equally puzzling. Again, only the patient who could eventually be weaned showed a marked in-ventricular remodeling" has been demonstrated during routine LVAD support before, especially with regard to crease in interstitial collagen deposition (from 6 to 19 arbitrary units). In the other patients, interstitial collagen geometry, function, cytokine levels, collagen content, and myocyte size (9, 17, 27, 28) . To what extent the ob-content remained largely unchanged.
served histologic changes in our weaned patient might DISCUSSION have been induced by the cell injection remains unclear. The histologic findings are particularly surprising be-In this pilot study we tested the hypothesis that autologous bone marrow mononuclear cells injected directly cause an increase in myocardial fibrosis is believed to indicate disease progression (3). It has indeed been sug-into the myocardium of patients with end-stage heart failure can increase the likelihood of weaning from gested that bone marrow-derived cells can modulate extracellular matrix turnover in the heart and thereby im-LVAD support. This hypothesis was not confirmed. Only 1 out of 10 patients was successfully weaned, and prove its function (8), but it is not clear whether a net increase in interstitial fibrosis in the clinical setting is this patient was a) the youngest of our cohort, and b) had probably postinflammatory heart failure with acute beneficial or deleterious. Cell therapy for heart disease has a brief but eventful decompensation. Considering the available data on patients weaned from VAD support as well as our clinical history (25) . The large-scale clinical introduction of skeletal myoblasts for heart failure patients seems to experience, this patient had a reasonable chance to recover even without cell therapy. In the other nine pa-have been abandoned, but data obtained in patients with LVAD devices gave valuable insight into the behavior tients, the clinical course, ultimately leading to heart transplantation, was not perceptibly altered by the cell of those cells in human myocardium (21) . More promising evidence came from studies that used enriched bone injection.
To collect more solid scientific data, a controlled pro-marrow stem cell products in cardiac surgical patients (12, 22, 24, 26) . Here, a significant additional gain in con-spective study would obviously be necessary. This is not impossible, but would involve tremendous logistic and tractile function was noted by independent groups, and multicenter, phase III analogous studies are currently be-ethical burdens in this rare cohort of extremely sick patients. It has been known for some time that weaning ing conducted. Because of their ease of manufacturing and relative inexpensiveness, autologous bone marrow from LVAD support is feasible in selected patients with myocarditis or idiopathic dilative cardiomyopathy (7, mononuclear cells have been used in the by far largest number of patients with ischemic heart disease and acute with standard treatment. The net "healing" capacity of BMC is therefore difficult to determine. In keeping with myocardial infarction (1, 23) . While their proangiogenic capacity in solid organs is undisputed, the resulting clin-the overall restraint view of bone marrow mononuclear cells for cardiac regenerative medicine, we found that ical benefit proved difficult to determine. One intrinsic problem is that most of those studies include many pa-such cell products do not visibly change the course of patients with end-stage heart disease. Although this no-tients with only moderately impaired heart function and thus little or no clinical symptoms and good prognosis tion is based on a small-scale pilot study, it may serve 
